Related Experiment Video

Updated: May 15, 2026

Malachite Green Assay for the Discovery of Heat-Shock Protein 90 Inhibitors
07:57

Malachite Green Assay for the Discovery of Heat-Shock Protein 90 Inhibitors

Published on: January 20, 2023

HSP90 inhibitors: current development and potential in cancer therapy

Katerina Sidera, Evangelia Patsavoudi1

  • 1Dept. of Biochemistry, Hellenic Pasteur Institute, 127, Vas. Sofias Av., 11521 Athens, Greece. epatsavoudi@pasteur.gr.

Recent Patents on Anti-Cancer Drug Discovery
|January 15, 2013
PubMed

Insights

Heat shock protein 90 (HSP90) is a key target in cancer therapy. Numerous HSP90 inhibitors are now in clinical trials, with ongoing drug discovery and patent activity.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • The molecular chaperone HSP90 plays a critical role in maintaining the transformed phenotype of cancer cells.
  • HSP90 is recognized as a significant therapeutic target in oncology.
  • Extensive drug discovery efforts have focused on HSP90 inhibitors.

Purpose of the Study:

  • To review the role of HSP90 in cancer.
  • To provide an overview of current HSP90 inhibitors in clinical development.
  • To update on recent patents related to HSP90 inhibitors.

Main Methods:

  • Literature review of HSP90's role in cancer.
  • Survey of clinical trial data for HSP90 inhibitors.
  • Analysis of recent patent filings for HSP90-targeting drugs.

Main Results:

  • HSP90 is crucial for cancer cell survival and proliferation.
  • Thirteen HSP90 inhibitors across various drug classes are in clinical evaluation.
  • Significant patent activity indicates continued innovation in HSP90 inhibitor development.

Conclusions:

  • HSP90 remains a promising target for cancer therapeutics.
  • The diverse range of inhibitors and ongoing research highlight the therapeutic potential.
  • Further development and clinical evaluation of HSP90 inhibitors are warranted.

More Related Videos

Exploring Biomolecular Interaction Between the Molecular Chaperone Hsp90 and Its Client Protein Kinase Cdc37 using Field-Effect Biosensing Technology09:39

Exploring Biomolecular Interaction Between the Molecular Chaperone Hsp90 and Its Client Protein Kinase Cdc37 using Field-Effect Biosensing Technology

Published on: March 31, 2022

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics08:29

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

Published on: October 2, 2014

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...